Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DROP and GO: Aflibercept + CAPOX for First-line mCRC
NCT02085005Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- Mar 2014
- Primary completion
- Aug 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in colorectal cancer (metastatic) (mCRC), sponsored by Sanofi. Primary endpoint: Progression-Free Survival rate at 10 months. Planned start Mar 2014; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02085005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085005.